Shruti Chaturvedi1, Keith R McCrae2. 1. Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37235, USA. 2. Department of Cellular and Molecular Medicine, Taussig Cancer Institute, Cleveland Clinic, CA6-154, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. mccraek@ccf.org.
Abstract
PURPOSE OF REVIEW: Laboratory criteria for the classification of antiphospholipid syndrome include the detection of a lupus anticoagulant and/or anticardiolipin and anti-β2-glycoprotein I antibodies. However, the majority of patients who test positive in these assays do not have thrombosis. Current risk-stratification tools are largely limited to the antiphospholipid antibody profile and traditional thrombotic risk factors. RECENT FINDINGS: Novel biomarkers that correlate with disease activity and potentially provide insight into future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other phospholipids or phospholipid/protein antigens (such as anti-PS/PT), and functional/biological assays such as thrombin generation, complement activation, levels of circulating microparticles, and annexin A5 resistance. Clinical risk scores may also have value in predicting clinical events. Biomarkers that predict thrombosis risk in patients with antiphospholipid antibodies have been long sought, and several biomarkers have been proposed. Ultimately, integration of biomarkers with established assays and clinical characteristics may offer the best chance of identifying patients at highest risk of APS-related complications.
PURPOSE OF REVIEW: Laboratory criteria for the classification of antiphospholipid syndrome include the detection of a lupus anticoagulant and/or anticardiolipin and anti-β2-glycoprotein I antibodies. However, the majority of patients who test positive in these assays do not have thrombosis. Current risk-stratification tools are largely limited to the antiphospholipid antibody profile and traditional thrombotic risk factors. RECENT FINDINGS: Novel biomarkers that correlate with disease activity and potentially provide insight into future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other phospholipids or phospholipid/protein antigens (such as anti-PS/PT), and functional/biological assays such as thrombin generation, complement activation, levels of circulating microparticles, and annexin A5 resistance. Clinical risk scores may also have value in predicting clinical events. Biomarkers that predict thrombosis risk in patients with antiphospholipid antibodies have been long sought, and several biomarkers have been proposed. Ultimately, integration of biomarkers with established assays and clinical characteristics may offer the best chance of identifying patients at highest risk of APS-related complications.
Authors: V Pengo; G Denas; E Bison; A Banzato; S Padayattil Jose; P Gresele; F Marongiu; N Erba; F Veschi; A Ghirarduzzi; E De Candia; B Montaruli; M Marietta; S Testa; D Barcellona; A Tripodi Journal: Thromb Res Date: 2010-06-09 Impact factor: 3.944
Authors: J Nojima; H Kuratsune; E Suehisa; Y Futsukaichi; H Yamanishi; T Machii; Y Iwatani; Y Kanakura Journal: Clin Chem Date: 2001-06 Impact factor: 8.327
Authors: M Ramos-Casals; M T Campoamor; A Chamorro; G Salvador; S Segura; J C Botero; J Yagüe; R Cervera; M Ingelmo; J Font Journal: Lupus Date: 2004 Impact factor: 2.911
Authors: Shruti Chaturvedi; Evan M Braunstein; Xuan Yuan; Jia Yu; Alice Alexander; Hang Chen; Eleni Gavriilaki; Ravi Alluri; Michael B Streiff; Michelle Petri; Mark A Crowther; Keith R McCrae; Robert A Brodsky Journal: Blood Date: 2020-01-23 Impact factor: 25.476
Authors: Paolo Durigutto; Claudia Grossi; Maria Orietta Borghi; Paolo Macor; Francesca Pregnolato; Elena Raschi; Michael P Myers; Philip G de Groot; Pier Luigi Meroni; Francesco Tedesco Journal: Haematologica Date: 2018-11-15 Impact factor: 9.941